Regulatory reference
China NMPA approval: no recognition regime
- Statement
TMDA's device registration framework (Control of Medical Devices Regulations 2015 and the June 2024 Compendium) subjects all Class A-D devices and IVDs to independent dossier assessment with no reference-authority list and no abridged pathway based on foreign approvals; TMDA's separate regulatory-reliance guideline (17 April 2025) covers marketing authorisation of human medicinal products only, and the only device-related reliance mechanism is the WHO Collaborative Registration Procedure for WHO-prequalified IVDs. An NMPA registration therefore gives no procedural benefit beyond documentary marketing-history evidence.
- Source Jurisdiction Id
china
- Source Authority Id
nmpa
- Source Approval
China NMPA medical device registration certificate (Class II/III) or Class I filing record
- Target Jurisdiction Id
tanzania
- China Classes In Scope
all device classes A (registrable), B, C, D and IVDs under standard registration
- Edge Type
No Reliance Route
- Market Access Strength
none
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Registration via online Trader Portal; ISO 13485 evidence for notification of Class A devices.
- WHO CRP applies only to WHO-prequalified IVDs (held fact).
- Independent verification is incomplete. Treat this record as a research lead, not a confirmed benefit or exclusion; see the 2026-09-15 independent review.
Effective from 2024-06-01
Source passage: According to The Tanzania Medicines and Medical devices (Control of Medical Devices) Regulations, 2015, all class A, B, C and D devices get market approval through registration while a selected class A devices attain market approval through notification. [...] For requirements for registration, please refer to Guidelines on Submission of Documentation for Registration of Medical Devices, third edition, April 2020 and Guidelines on submission of Documentation for Registration of In-vitro Diagnostic Devices, third edition, April 2020

